A Phase 2 interventional study of VAY736 and Placebo in Primary Sjögren's Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS patients
Patients were enrolled in 2 sequential cohorts:
Cohort 1: 6 patients received 3 mg/kg or Placebo (2:1 ratio) Cohort 2: 21 patients received 10 mg/kg, 3 mg/kg or Placebo (6:1:3 ratio)
At week 24 the blind was broken to assess continuation in the trial:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA:
Hydroxychloroquine or methotrexate in a consistent dose for ≥ 3 months prior to randomization is allowed
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose iv of VAY736 at a dose of 3mg/kg
Drug: VAY736
single dose iv of VAY736 at a dose of 10mg/kg
Drug: VAY736
single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.
Drug: Placebo
Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)
The effect of VAY736 on clinical disease activity was measured by the change in ESSDAI (EULAR Sjögren's syndrome disease activity index) between baseline and week 12. The instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score (range 0-123). A reduction from baseline indicates improvement in patients.
Time frame: Baseline, week 12
Overall Incidence of Adverse Events
Number of subjects with Adverse Events during the double blind treatment period.
Time frame: Baseline to Week 24
Change in EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)
The ESSPRI is a patient self-reported outcome measure to assess dryness, limb pain, fatigue and mental fatigue, where each of the domains normally reported as 0 (not at all) to 10 (extremely severe). The final ESSPRI score is the average of three: dryness, pain and fatigue. A reduction from baseline indicates the improvement of symptoms. During the study all individual scores were reported as 1 to 10 instead. A linear transformation was reported to map the scores to the range of 0-10.
Time frame: Baseline, week 12
Change in Short Form (36) Health Survey (SF-36)
The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.
Time frame: Baseline, week 12
Change in Multidimensional Fatigue Inventory (MFI)
The MFI is a patient self-reported outcome measure (questionnaires) to assess fatigue covering the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each dimension has a posible range from 4-20. A reduction from baseline in MFI indicates improvement.
Time frame: Baseline, week 12
Change in the Physician's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)
The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).
Time frame: Baseline, week 12
Change in the Patient's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)
The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).
Time frame: Baseline, week 12
VAY736 Serum Concentration - AUCinf
The area under the serum concentration-time curve from time zero to infinity \[mass × time / volume\]. The concentration of VAY736 was measured in the serum.
Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
VAY736 Serum Concentration - AUClast
The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration \[mass × time / volume\]. The concentration of VAY736 was measured in the serum.
Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
VAY736 Serum Concentration - CL
The systemic (or total body) clearance from serum following intravenous administration \[volume / time\]. The concentration of VAY736 was measured in the serum.
Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
VAY736 Serum Concentration - Cmax
The observed maximum serum concentration following drug administration \[mass / volume\]. The concentration of VAY736 was measured in the serum.
Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
VAY736 Serum Concentration - T1/2
Apparent terminal half-life, determined as the ln2/lambda_z or 0.693/lambda_z. The concentration of VAY736 was measured in the serum.
Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
VAY736 Serum Concentration - Tmax
The time to reach the maximum concentration after drug administration \[time\]. The concentration of VAY736 was measured in the serum.
Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
VAY736 Serum Concentration - Vz
The volume of distribution during the terminal elimination phase following intravenous administration \[volume\]. The concentration of VAY736 was measured in the serum.
Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
A total of 27 patients were enrolled and randomized into the study at one site in Germany.
| Milestone | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg |
|---|---|---|---|
| Started | 9 | 6 | 12 |
| Safety analysis set | 9 | 6 | 12 |
| Pk analysis set | 5 | 6 | 12 |
| Pd (pharmacodynamics) analysis set | 9 | 6 | 12 |
| Completed | 9 | 5 | 10 |
| Not completed | 0 | 1 | 2 |
| Withdrew: Administrative problems | 0 | 1 | 2 |
| Milestone | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg |
|---|---|---|---|
| Started | 5 | 0 | 0 |
| Completed | 4 | 0 | 0 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Administrative problems | 1 | 0 | 0 |
The effect of VAY736 on clinical disease activity was measured by the change in ESSDAI (EULAR Sjögren's syndrome disease activity index) between baseline and week 12. The instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score (range 0-123). A reduction from baseline indicates improvement in patients.
| units on a scale | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg | VAY736 Combined |
|---|---|---|---|---|
| Baseline | 11.1 ± 4.08 | 14.5 ± 9.44 | 11.5 ± 4.38 | 12.5 ± 6.38 |
| Week 12 | 10.2 ± 5.29 | 10.7 ± 7.69 | 10.0 ± 5.36 | 10.2 ± 6.01 |
| Change from Baseline to Week 12 | -0.9 ± 2.98 | -3.8 ± 8.66 | -1.5 ± 3.00 | -2.3 ± 5.40 |
The ESSPRI is a patient self-reported outcome measure to assess dryness, limb pain, fatigue and mental fatigue, where each of the domains normally reported as 0 (not at all) to 10 (extremely severe). The final ESSPRI score is the average of three: dryness, pain and fatigue. A reduction from baseline indicates the improvement of symptoms. During the study all individual scores were reported as 1 to 10 instead. A linear transformation was reported to map the scores to the range of 0-10.
| units on a scale | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg |
|---|---|---|---|
| Baseline | 5.967 ± 2.2179 | 6.049 ± 1.2759 | 6.235 ± 1.5379 |
| Week 12 | 5.926 ± 1.5822 | 6.173 ± 1.4753 | 4.568 ± 2.5966 |
| Change from Baseline to Week 12 | -0.041 ± 1.7805 | 0.123 ± 1.0120 | -1.667 ± 1.8918 |
The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.
| units on a scale | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg |
|---|---|---|---|
| Physical component score: Baseline | 46.886 ± 6.3905 | 39.445 ± 4.2857 | 46.015 ± 9.3533 |
| Physical component score: Week 12 | 44.788 ± 8.3513 | 45.493 ± 7.3060 | 47.671 ± 9.2804 |
| Physical component score: Change from Baseline | -2.098 ± 7.9084 | 6.048 ± 4.7189 | 1.656 ± 5.4113 |
| Mental component score: Baseline | 36.913 ± 15.2776 | 37.517 ± 6.8994 | 43.628 ± 11.3667 |
| Mental component score: Week 12 | 41.012 ± 13.2991 | 40.170 ± 11.9815 | 46.700 ± 11.3182 |
| Mental component score: Change from Baseline | 4.099 ± 5.3361 | 2.653 ± 17.1261 | 3.073 ± 11.5823 |
The MFI is a patient self-reported outcome measure (questionnaires) to assess fatigue covering the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each dimension has a posible range from 4-20. A reduction from baseline in MFI indicates improvement.
| units on a scale | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg |
|---|---|---|---|
| General Fatigue: Baseline | 14.0 ± 4.72 | 17.0 ± 2.37 | 15.9 ± 3.34 |
| General Fatigue: Week 12 | 12.8 ± 4.84 | 14.2 ± 6.40 | 12.4 ± 3.99 |
| General Fatigue: Change from Baseline | -1.2 ± 1.64 | -2.8 ± 5.04 | -3.5 ± 4.12 |
| Physical Fatigue: Baseline | 12.9 ± 4.14 | 15.7 ± 2.34 | 14.2 ± 3.41 |
| Physical Fatigue: Week 12 | 12.2 ± 3.99 | 11.2 ± 5.15 | 10.4 ± 4.66 |
| Physical Fatigue: Change from Baseline | -0.7 ± 1.32 | -4.5 ± 6.57 | -3.8 ± 4.77 |
| Mental Fatigue: Baseline | 11.9 ± 4.78 | 14.3 ± 3.78 | 13.0 ± 3.28 |
| Mental Fatigue: Week 12 | 11.7 ± 4.12 | 11.3 ± 4.18 | 9.8 ± 5.17 |
| Mental Fatigue: Change from Baseline | -0.2 ± 2.95 | -3.0 ± 6.07 | -3.2 ± 5.84 |
| Reduced motivation: Baseline | 12.4 ± 4.93 | 12.3 ± 3.93 | 10.9 ± 2.68 |
| Reduced motivation: Week 12 | 12.0 ± 5.32 | 10.0 ± 4.52 | 9.8 ± 4.97 |
| Reduced motivation: Change from Baseline | -0.4 ± 2.40 | -2.3 ± 4.50 | -1.1 ± 4.56 |
| Reduced activity: Baseline | 11.8 ± 2.86 | 10.8 ± 1.72 | 12.2 ± 2.69 |
| Reduced activity: Week 12 | 10.4 ± 3.81 | 8.7 ± 3.61 | 9.3 ± 5.08 |
| Reduced activity: Change from Baseline | -1.3 ± 1.80 | -2.2 ± 4.83 | -2.9 ± 4.25 |
The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).
| units on a scale | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg |
|---|---|---|---|
| Baseline | 57.3 ± 17.73 | 66.2 ± 17.53 | 65.0 ± 11.74 |
| Week 12 | 59.8 ± 23.35 | 43.0 ± 23.82 | 48.5 ± 17.33 |
| Change from Baseline to Week 12 | 2.4 ± 12.21 | -23.2 ± 31.10 | -16.5 ± 18.96 |
The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).
| units on a scale | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg |
|---|---|---|---|
| Baseline | 56.2 ± 24.86 | 67.2 ± 13.69 | 59.8 ± 24.30 |
| Week 12 | 55.2 ± 21.57 | 44.2 ± 22.75 | 40.8 ± 20.49 |
| Change from Baseline to Week 12 | -1.0 ± 17.71 | -23.0 ± 25.73 | -19.0 ± 21.08 |
The area under the serum concentration-time curve from time zero to infinity \[mass × time / volume\]. The concentration of VAY736 was measured in the serum.
| day*ug/mL | VAY736 3 mg/kg | VAY736 10 mg/kg | Open Label VAY736 |
|---|---|---|---|
| VAY736 Serum Concentration - AUCinf | 389 (186 to 457) | 1140 (515 to 1610) | 971 (849 to 1340) |
The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration \[mass × time / volume\]. The concentration of VAY736 was measured in the serum.
| day*ug/mL | VAY736 3 mg/kg | VAY736 10 mg/kg | Open Label VAY736 |
|---|---|---|---|
| VAY736 Serum Concentration - AUClast | 385 (184 to 457) | 1140 (514 to 1610) | 971 (848 to 1340) |
The systemic (or total body) clearance from serum following intravenous administration \[volume / time\]. The concentration of VAY736 was measured in the serum.
| L/day | VAY736 3 mg/kg | VAY736 10 mg/kg | Open Label VAY736 |
|---|---|---|---|
| VAY736 Serum Concentration - CL | 0.594 (0.427 to 0.844) | 0.584 (0.550 to 1.30) | 0.686 (0.427 to 0.750) |
The observed maximum serum concentration following drug administration \[mass / volume\]. The concentration of VAY736 was measured in the serum.
| ug/mL | VAY736 3 mg/kg | VAY736 10 mg/kg | Open Label VAY736 |
|---|---|---|---|
| VAY736 Serum Concentration - Cmax | 65.0 (45.4 to 76.5) | 213 (150 to 283) | 205 (174 to 217) |
Apparent terminal half-life, determined as the ln2/lambda_z or 0.693/lambda_z. The concentration of VAY736 was measured in the serum.
| days | VAY736 3 mg/kg | VAY736 10 mg/kg | Open Label VAY736 |
|---|---|---|---|
| VAY736 Serum Concentration - T1/2 | 8.43 (6.99 to 13.8) | 9.51 (5.38 to 15.2) | 11.0 (4.94 to 17.4) |
The time to reach the maximum concentration after drug administration \[time\]. The concentration of VAY736 was measured in the serum.
| hours | VAY736 3 mg/kg | VAY736 10 mg/kg | Open Label VAY736 |
|---|---|---|---|
| VAY736 Serum Concentration - Tmax | 2.03 (2.00 to 2.20) | 2.03 (2.00 to 2.30) | 2.10 (2.02 to 2.17) |
The volume of distribution during the terminal elimination phase following intravenous administration \[volume\]. The concentration of VAY736 was measured in the serum.
| L | VAY736 3 mg/kg | VAY736 10 mg/kg | Open Label VAY736 |
|---|---|---|---|
| VAY736 Serum Concentration - Vz | 7.83 (6.55 to 10.7) | 8.68 (7.15 to 12.4) | 10.3 (4.93 to 18.6) |
Number of subjects with Adverse Events during the double blind treatment period.
| Participants | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg | VAY736 Combined |
|---|---|---|---|---|
| Subjects with AEs | 8 | 6 | 11 | 17 |
| Subjects with AEs within 24hr of infusion | 2 | 6 | 11 | 17 |
| Subjects with AEs post 24hr of infusion | 8 | 6 | 8 | 14 |
| Subjects with Study drug-related AEs | 5 | 6 | 11 | 17 |
| Subjects with Infusion related AEs | 1 | 6 | 9 | 15 |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date subject has provided informed consent until end of study (Week 28 or when B cell recovery was demonstrated, up to 3 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| VAY736 3mg/kg | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| VAY736 10mg/kg | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Open Label VAY736 10mg/kg | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Event | Placebo | VAY736 3mg/kg | VAY736 10mg/kg | Open Label VAY736 10mg/kg |
|---|---|---|---|---|
| Inguinal herniaGastrointestinal disorders | 0/9 | 0/6 | 0/12 | 1/5 |
| Jaw fractureInjury, poisoning and procedural complications | 0/9 | 1/6 | 0/12 | 0/5 |
| Ovarian cyst torsionReproductive system and breast disorders | 0/9 | 1/6 | 0/12 | 0/5 |
| ColitisGastrointestinal disorders | 1/9 | 0/6 | 0/12 | 0/5 |
| AppendicitisInfections and infestations | 1/9 | 0/6 | 0/12 | 0/5 |
| Event | Placebo | VAY736 3mg/kg | VAY736 10mg/kg | Open Label VAY736 10mg/kg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/9 | 5/6 | 4/12 | 5/5 |
| Infusion related reactionInjury, poisoning and procedural complications | 1/9 | 6/6 | 9/12 | 3/5 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/9 | 2/6 | 0/12 | 0/5 |
| HeadacheNervous system disorders | 3/9 | 2/6 | 2/12 | 1/5 |
| Non-cardiac chest painGeneral disorders | 2/9 | 0/6 | 0/12 | 0/5 |
| PalpitationsCardiac disorders | 0/9 | 0/6 | 0/12 | 1/5 |
| Vitreous detachmentEye disorders | 1/9 | 0/6 | 0/12 | 1/5 |
| ToothacheGastrointestinal disorders | 0/9 | 0/6 | 0/12 | 1/5 |
| BronchitisInfections and infestations | 0/9 | 0/6 | 0/12 | 1/5 |
| ConjunctivitisInfections and infestations | 0/9 | 0/6 | 1/12 | 1/5 |
| Age, Continuous(Years) | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg | Total |
|---|---|---|---|---|
| Mean | 46.7 ± 11.29 | 46.8 ± 8.75 | 55.3 ± 13.35 | 50.5 ± 12.16 |
| Sex: Female, Male(Participants) | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg | Total |
|---|---|---|---|---|
| Female | 7 | 5 | 11 | 23 |
| Male | 2 | 1 | 1 | 4 |
| Race/Ethnicity, Customized(Participants) | Placebo | VAY736 3 mg/kg | VAY736 10 mg/kg | Total |
|---|---|---|---|---|
| Caucasian | 9 | 6 | 12 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2014 to primary completion in Feb 2018, 44 months.
Results were first posted in Feb 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ianalumab